WSG and CANKADO's EnReP predicts the benefits of anti-hormone therapy in breast cancer patients
The tool developed on the basis of the ADAPT study data will be presented today at SABCS 2020 Cologne, Germany, 11.12.2020 – The EnReP (Endocrine Response Predictor) assessment tool will be presented today at the San Antonio Breast Cancer Symposium SABCS 2020. EnReP is a tool developed in Germany that can be used to predict the probability of response to endocrine therapy in early-stage breast cancer patients. Endocrine therapy is the standard therapy for hormone receptor-positive (HR+) / HER2-negative (HER2-) breast cancer patients. The ADAPT study program evaluates options for patient-spe...